- Home
- FLGC vs SABS Comparison
FLGC vs SABS Comparison
Compare FLGC & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLGC
- SABS
- Stock Information
- Founded
- FLGC 2019
- SABS 2014
- Country
- FLGC United States
- SABS United States
- Employees
- FLGC N/A
- SABS N/A
- Industry
- FLGC Biotechnology: Pharmaceutical Preparations
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- FLGC Health Care
- SABS Health Care
- Exchange
- FLGC Nasdaq
- SABS Nasdaq
- Market Cap
- FLGC 17.3M
- SABS 11.4M
- IPO Year
- FLGC 2021
- SABS N/A
- Fundamental
- Price
- FLGC $0.54
- SABS $1.44
- Analyst Decision
- FLGC Strong Buy
- SABS Strong Buy
- Analyst Count
- FLGC 3
- SABS 5
- Target Price
- FLGC $5.00
- SABS $11.40
- AVG Volume (30 Days)
- FLGC 175.1K
- SABS 23.4K
- Earning Date
- FLGC 05-13-2025
- SABS 05-19-2025
- Dividend Yield
- FLGC N/A
- SABS N/A
- EPS Growth
- FLGC N/A
- SABS N/A
- EPS
- FLGC N/A
- SABS N/A
- Revenue
- FLGC $59,505,000.00
- SABS $1,322,410.00
- Revenue This Year
- FLGC $4.28
- SABS N/A
- Revenue Next Year
- FLGC N/A
- SABS $50.00
- P/E Ratio
- FLGC N/A
- SABS N/A
- Revenue Growth
- FLGC N/A
- SABS N/A
- 52 Week Low
- FLGC $0.42
- SABS $1.00
- 52 Week High
- FLGC $2.11
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- FLGC 44.07
- SABS 49.70
- Support Level
- FLGC $0.44
- SABS $1.00
- Resistance Level
- FLGC $0.52
- SABS $1.48
- Average True Range (ATR)
- FLGC 0.06
- SABS 0.14
- MACD
- FLGC 0.01
- SABS 0.05
- Stochastic Oscillator
- FLGC 51.75
- SABS 83.65
About FLGC Flora Growth Corp.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are; the commercial and wholesale segment (FGH and Cosechemos subsidiaries), the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries), and the pharmaceuticals segment (Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries). Geographically, the company generates revenue from United States, Germany, and the United Kingdom. It derives a majority of its revenue from the United States.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.